| He, Zhisong |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
NCT04568304: A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Not yet recruiting | 3 | 364 | RoW | Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Locally Advanced or Metastatic Urothelial Carcinoma | 11/23 | 11/25 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT06227156: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Disitamab Vedotin Injection, DV,RC48 | RemeGen Co., Ltd. | Castration-resistant Prostate Cancer | 12/25 | 06/26 | | |
RC48-C017, NCT05297552: A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 40 | RoW | RC48-ADC, JS001 | RemeGen Co., Ltd. | Muscle Invasive Bladder Carcinoma | 06/24 | 02/25 | | |
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 246 | RoW | Axitinib plus Toripalimab, nephrectomy | ZHOU FANGJIAN, Pfizer | Renal Cell Carcinoma, Neoadjuvant | 07/25 | 03/26 | | |
NCT06029036: A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Darolutamide+ADT | Peking University First Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Xijing Hospital of Air Force Military Medical University | Prostate Cancer | 07/25 | 07/26 | | |
| Recruiting | 2 | 240 | Europe, Canada, US, RoW | SKB264, Pembrolizumab, Keytruda | Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc. | Solid Tumor | 11/26 | 12/27 | | |
NCT05943379: RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects |
|
|
| Recruiting | 2 | 85 | RoW | RC48-ADC in Combination with gemcitabine | RemeGen Co., Ltd. | NMIBC | 12/25 | 12/26 | | |
NCT06732531: Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 48 | RoW | BH011, Docetaxel | Zhuhai Beihai Biotech Co., Ltd | Bladder Cancer, Non Muscle Invasive | 12/25 | 12/25 | | |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
NCT05410730: A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC |
|
|
| Recruiting | 1/2 | 150 | RoW | SHR-1501 | Shanghai Hengrui Pharmaceutical Co., Ltd. | High-risk NMIBC | 05/25 | 05/27 | | |
NCT05393427: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors | 06/25 | 06/25 | | |
NCT05973149: Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer |
|
|
| Not yet recruiting | 1 | 108 | RoW | QLH12016 | Qilu Pharmaceutical Co., Ltd. | Prostate Cancer | 08/25 | 01/26 | | |
NCT06317298: Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy |
|
|
| Recruiting | N/A | 36 | RoW | Fruquintinib and Everolimus | Peking University First Hospital | Renal Cell Carcinoma, Clear Cell, Somatic | 08/25 | 12/25 | | |
| Xu, Quangang |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT03586557: Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis |
|
|
| Recruiting | N/A | 142 | RoW | Corticosteroid & Plasma exchange, CS+PE, Corticosteroid, CS | Chinese PLA General Hospital | Optic Neuritis | 12/21 | 12/21 | | |
| Li, Weiping |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 60 | RoW | microtransplantation, HLA-mismatched donor peripheral stem cell infusion, DSI | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Ovarian Cancer Recurrent | 10/23 | 10/25 | | |
NCT04794972: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 147 | RoW | GNC-039 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Recurrent Glioma, Solid Tumor | 06/25 | 06/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
